SelectQuote (SLQT) Shows Fast-paced Momentum But Is Still a Bargain Stock
SelectQuote (SLQT) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
SelectQuote (SLQT) Upgraded to Strong Buy: What Does It Mean for the Stock?
SelectQuote (SLQT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Here Is Why Bargain Hunters Would Love Fast-paced Mover SelectQuote (SLQT)
SelectQuote (SLQT) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Should Value Investors Buy SelectQuote (SLQT) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
SelectQuote, Inc. (SLQT) Q3 2026 Earnings Call Transcript
SelectQuote, Inc. (SLQT) Q3 2026 Earnings Call Transcript
After Plunging 27.0% in 4 Weeks, Here's Why the Trend Might Reverse for SelectQuote (SLQT)
The heavy selling pressure might have exhausted for SelectQuote (SLQT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
SelectQuote, Inc. (SLQT) Q2 2026 Earnings Call Transcript
SelectQuote, Inc. (SLQT) Q2 2026 Earnings Call Transcript
SelectQuote Q2 Earnings Preview: Sell The Medicare Reimbursement News (Rating Downgrade)
SelectQuote is downgraded to sell as Medicare Advantage reimbursement shocks threaten its core business model. SLQT's fundamentals are deteriorating, with Senior segment profitability slipping and commission revenue at risk from insurer belt-tightening. The 2027 Medicare reimbursement rate increase of just 0.09% is far below expectations, likely pressuring insurer and broker margins.
SelectQuote: Shaky Carrier Trends Rattle My Confidence (Downgrade)
SelectQuote faces mounting challenges, including weaker growth in its core SelectRx segment and heightened industry headwinds impacting policy sales and retention. SLQT's revenue mix is shifting toward recurring pharmacy benefits, but razor-thin margins and recent member losses raise concerns about long-term profitability. Despite trading at a low 5x EV/FY26 adjusted EBITDA, SLQT's high debt load and uncertain outlook make its valuation less compelling.
SelectQuote, Inc. (SLQT) Q1 2026 Earnings Call Transcript
SelectQuote, Inc. ( SLQT ) Q1 2026 Earnings Call November 6, 2025 8:30 AM EST Company Participants Matthew Gunter Timothy Danker - CEO & Director Ryan Clement - Chief Financial Officer William Grant - Chief Operating Officer Conference Call Participants Michael Murray - RBC Capital Markets, Research Division Patrick McCann - NOBLE Capital Markets, Inc., Research Division Presentation Operator Welcome to SelectQuote's First Quarter Earnings Conference Call. [Operator Instructions] It is now my pleasure to introduce Matt Gunter, SelectQuote Investor Relations.
SelectQuote (SLQT) Reports Q1 Loss, Tops Revenue Estimates
SelectQuote (SLQT) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.26 per share a year ago.
SelectQuote: Efficiency Is The Name Of The Game, A Strong FY26 Ahead
Market rotation favors growth at a reasonable price; SelectQuote, Inc. is an under-the-radar opportunity with strong upside potential. SelectQuote's FY26 guidance is bullish, with 11% revenue growth and 7% adjusted EBITDA growth, yet the stock remains modestly valued. SelectQuote is stabilizing its business with recurring revenue from its SelectRx division, and is expected to deliver higher profit over time (up to a goal of 20% adjusted EBITDA margins).
